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1. Introduction  
Syk (spleen tyrosine kinase) is a nonreceptor tyrosine kinase containing two tandem 
amino-terminal SH2 domains, followed by an extended linker region and a carboxy-
terminal kinase domain (Sada et al., 2001). Tyrosine-352 (Y352) in the linker region is 
trans-phosphorylated by src family members, promoting the activation of syk (Kimura et 
al., 1996; Sada et al., 2001). Activation further involves the autophosphorylation of syk on 
tyrosines 525 and 526 (YY525/6) in the activation loop of the kinase domain, which 
promotes substrate-specific catalytic activity and is required for signaling by syk (Sada et 
al., 2001; Zhang et al., 1998); this modification is thus indicative of the functional enzyme. 
The active form of syk then localizes to appropriate substrates or bridging molecules 
primarily through interactions with its SH2 domains and linker tyrosines (Kimura et al., 
1996; Sada et al., 2001). 
Syk has been identified as a putative tumor suppressor in human breast cancer since 
reintroduction of syk retarded the growth of syk-negative breast cancer cells, and 
suppression of endogenous syk enhanced the tumorigenic phenotype of the resulting cells 
(Coopman et al., 2000). Loss of syk correlates with poor survival and metastasis of breast 
cancer in patients (Toyama et al., 2003), and syk regulates breast cancer cell mitosis (Zyss et 
al., 2005) and transcription (Wang et al., 2005). Previously we identified syk as being a 
pancreatic ductal adenocarcinoma (PDAC) tumor suppressor. Syk is uniformly expressed by 
normal pancreatic ductal epithelium and well-differentiated (grade1; G1) PDAC; however 
moderately-differentiated (grade2; G2) PDAC demonstrates progressive loss of syk, and 
high-grade (grade3; G3), poorly-differentiated lesions are essentially devoid of syk in situ 
(Layton et al., 2009). In fact, syk expression is a strong positive indicator of patient survival 
(Layton et al., 2009). Mechanistically, we demonstrated that syk is a central mediator of 
phenotypic changes regulating PDAC progression, including anchorage-independent 
growth, cellular invasion, and gene expression changes responsible for epithelial-
mesenchymal transition (Layton et al., 2009). To assess the utilization of syk in pancreatic 
ductal cells, we examined phosphorylation states of syk that correspond to upstream 
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activation (tyrosine-352) and catalytic activity (tyrosines-525/6). We further examined the 
activity of syk and the requirement for syk kinase activity in regulating cell growth and 
invasion. Herein we show that although blockade of syk activity suppressed growth of 
endogenously syk-positive PDAC cells in vitro, kinase activity is not required for syk-
dependent regulation of PDAC cell invasion. Phosphorylation of tyrosine-352 and tyrosines-
525/6 is detectable in pancreatic ductal epithelial cells in situ and in vitro, and inhibition of 
syk kinase activity specifically retards the growth of endogenously syk-positive PDAC cells 
in vitro. In contrast to our previous demonstration that syk regulates the invasion of v3-
positive Panc1 PDAC cells by attenuation of the matrix metalloproteinase-2 axis (Layton et 
al., 2009), invasion of v3-negative MIAPaCa2 and BxPC3 PDAC cells is metalloproteinase-
independent and involves the urokinase/plasminogen system, which is regulated by syk in 
these cells. Thus we demonstrate that endogenous syk is active in pancreatic ductal 
epithelial cells, and that syk kinase activity is required for growth regulation, but not 
invasion suppression, by syk in this cell type.  
2. Materials and methods 
2.1 Cell lines and transfection  
CAPAN2(G1), CFPAC1(G2), AsPC1(G2), BxPC3(G2), Panc1(G3) and MIAPaCa2(G3+) cells 
were originally from ATCC and cultured accordingly. pCDNA3.1/IH/sykwt encoding myc-
tagged human syk linked to a hygromycin phosphotransferase gene through an IRES was 
described previously (Layton et al., 2009). Kinase-dead (KD) syk was produced by  
site-directed mutagenesis of lysine-402 in the ATP-binding pocket of  
pCDNA3.1/IH/sykwt using the following primers (K402R-FWD: 5’-
GTGAAAACCGTGGCTGTGAGAATACTGAAAAACGAGGC-3’; K402R-REV: 5’-
GCCTCGTTTTTCAGTATTCTCACAGCCACGGTTTTCAC-3’). MIAPaCa2 cells were 
transfected using Lipofectamine2000 (Invitrogen, Carlsbad, CA). BxPC3 cells were 
electroporated as described previously (Layton et al., 2009). Stable populations were 
hygromycin-selected and assessed for protein expression. For transient studies, pEF4-LacZ 
reporter (Invitrogen, Carlsbad, CA) was cotransfected, and cells stained with x-gal to identify 
and specifically quantitate transfected cells; average MIAPaCa2 transfection efficiency >95%. 
In all cases, serum-free (SF-) media consisted of all components except serum, as appropriate 
for the cell line, supplemented with 0.5% bovine serum albumin (BSA). 
2.2 Antibodies and reagents  
Anti-syk mAb 4D10 and anti-erk2 pAb C14 were from Santa Cruz Biotechnology (Santa 
Cruz, CA). Anti-syk phospho-Y352 and anti-syk phospho-YY525/6 pAbs were from Cell 
Signaling (Beverly, MA). Anti-phosphotyrosine mAb 4G10 and anti-myc tag mAb 4A6 were 
from UBI (Lake Placid, NY). Function-blocking anti-integrin antibodies LM609 (v3) and 
PIF6 (v5) and the MMP inhibitor N-(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-
methylpentanoyl-L-napthylalanyl-L-alanine, 2-aminoethylamide (TAPI-1) were from 
Chemicon/EMD (San Diego, CA). Function-blocking anti-uPA mAb 3689 was from 
American Diagnostica (Stamford, CT). HRP- and FITC-conjugated secondary antibodies 
were from Jackson Immunoresearch Laboratories (West Grove, PA). Nonspecific mouse 
IgG1 antibody MOPC-21, purified rabbit IgG, piceatannol (3,4,3’,5’- tetrahydroxy-trans-
stilbene), Crystal Violet and other chemicals were from Fisher Scientific (Pittsburg, PA). 
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2.3 Immunohistochemistry 
Patient tissue samples were obtained under approved UCSD Institutional Review Board 
protocol from the UCSD Dept. of Pathology archives and stained essentially as described 
previously (Layton et al., 2009). Briefly, samples were deparaffinized with xylenes, 
rehydrated through sequential alcohols (100%, 95%, 70%, 50%), and incubated with 1% H2O2 
to inactivate endogenous peroxidases. Slides were quenched with 50 mM glycine, and 
blocked with 2% horse serum/5% BSA/phosphate-buffered saline (PBS), pH7.4, before 
renaturing for 20min in a steamer using Target Retrieval Solution (DAKO North America; 
Carpinteria, CA). Slides were allowed to cool and then incubated with the appropriate 
primary antibody overnight at 4˚C. Slides were washed and biotinylated-anti-rabbit applied 
according to the VectaStain Elite ABC Kit (Vector Labs; Burlingame, CA, USA). Sections 
were developed with DAB, counterstained with hematoxylin, dehydrated through 
sequential alcohols and mounted. Brightfield images were acquired on a Nikon TE600 
microscope with a Model 3.2.0 CCD camera (Diagnostic Instruments, Sterling Heights, MI, 
USA) using SpotBasic software at the Moores UCSD Cancer Center. 
2.4 Immunoblotting 
Immunoblotting was performed essentially as described previously (Chen et al., 2010). 
Briefly, cells were lysed on the plate in NP40 lysis buffer (50mM Tris pH7.4, 150mM NaCl, 
1% NP-40) containing Complete™ Protease Inhibitor Cocktail (Roche, Indianapolis, IN) 
supplemented with 10mM PMSF, 1mM NaF and 10mM Na3VO4. Samples were separated by 
SDS-PAGE under reducing conditions and electroblotted to a PVDF membrane. Membranes 
were blocked with 10% nonfat dry milk in tris-buffered saline (TBS) containing 0.1% Tween-
20 (TBS-T) and incubated 2h to overnight in 2% milk/TBS-T with the indicated primary 
antibody. Primary antibody was detected with HRP-conjugated secondary antibody, and 
complexes were visualized by enhanced chemiluminescence with PS-3 (Lumigen, Inc.; 
Southfield, MI). 
2.5 Flow cytometry (FACS) 
FACS was performed on a FACScalibur (BD Biosciences, Bedford, MA) at the Moores UCSD 
Cancer Center Flow Cytometry Shared Resource as described previously (Chen et al., 2010). 
Cells were harvested with 0.1% trypsin/versene, inactivated with 0.1% soybean trypsin 
inhibitor and resuspended in FACS buffer (1mM MgCl2, 1mM CaCl2, 0.1% NaN3 0.5% BSA 
in PBS pH 7.4) before sequential labelling with primary and FITC-conjugated secondary 
antibodies. Gates were set with secondary alone, and 5μg/ml propidium iodide was 
included to exclude dead and dying cells. 
2.6 Proliferation assays 
Cell growth was assessed with the CellTiter96 Aqueous One Solution Cell Proliferation 
Assay (MTS) kit (Promega, Madison, WI), or as follows: cells (5x102/well) were seeded into 
a 48-well plate. After 24 hours (and every 72 hours thereafter), fresh growth medium was 
replaced and the initial time point fixed with 1% paraformaldehyde/PBS, pH7.4. Additional 
triplicate wells were fixed at 24 hour intervals. All wells were stained with 1% Crystal 
Violet, which was subsequently extracted with 10% acetic acid, quantitated at 550nm and 
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compared to a standard curve of cells. For proliferation assays in the presence of the syk 
inhibitor, piceatannol, a titration of cells was plated and allowed to adhere for 24 hours before 
fresh growth medium (full serum) containing the indicated concentrations of piceatannol or 
DMSO vehicle was replaced. Medium was replenished in the same manner every other day 
for a total of 3 treatments, and the cells were fixed and stained with Crystal Violet 24h after the 
last treatment. Dye was extracted with 10% acetic acid and quantitated at 550nm. 
2.7 Anchorage-independent growth 
Anchorage-independent growth was assessed as described previously (Layton et al., 2009). 
Briefly, a top layer containing 5x103 cells in 0.5% agar/DMEM/10%FBS was seeded onto a 
base layer of 0.7% agar/DMEM containing 10% FBS in a 6 well plate. Cultures were 
incubated at 37°C, media was replaced every 3rd day, and the assay stopped on day 10. 
Cultures were stained with 0.01% Crystal Violet and colonies were enumerated on a Bio-
Rad GelDocXR using QuantityOne Software (Sensitivity=8.1, Average=5). 
2.8 Invasion assay 
Invasion assays were performed as described previously (Layton et al., 2009) using BioCoat 
Growth Factor-Reduced Matrigel Invasion Chambers (BD Biosciences, Bedford, MA, USA). 
Briefly, cells were applied in SF-media to the upper chamber with or without 15min 
preincubation with TAPI1 (40μg/mL), aprotinin (100μg/mL), anti-uPA monoclonal 
antibody 3689 (25μg/mL), nonspecific IgG1 control antibody MOPC-21 (25g/ml), or an 
equal volume of DMSO or PBS control included in both chambers. SF-media or growth 
media was provided in the lower chamber and cells were allowed to invade for 24h before 
removal of uninvaded cells, and enumeration of invaded cells. 
2.9 Reverse Transcription (RT)-PCR 
cDNA was synthesized from 1μg of total RNA using oligo-dT primer. PCR was performed 
on 1μL of resulting cDNA using primers described previously (Layton et al., 2009; Leissner 
et al., 2006). GAPDH primers were from Stratagene (San Diego, CA) and served as internal 
controls. Densitometry was performed on unadjusted images using NIH Image 1.61 software 
and GAPDH as reference control. 
2.10 Statistics 
Experiments were performed in triplicate and independently repeated at least twice. Data 
shown are mean + standard deviation unless otherwise indicated. Colony-formation and 
cellular invasion were analyzed by two-tailed Students t-Test. 
3. Results  
3.1 Endogenously–expressed syk is functional in pancreatic ductal cells in situ and in 
vitro 
Previously we demonstrated the expression of syk in normal pancreatic ductal epithelial 
cells in situ (Layton et al., 2009). In order to assess whether this endogenous syk is 
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functionally active, we performed immunohistochemistry with antibodies specific for the 
phosphorylated form of Y352, which is representative of syk activation by upstream 
mediators, or YY525/6, which is indicative of substrate-specific activity of the syk kinase 
domain (Kimura et al., 1996; Sada et al., 2001; Zhang et al., 1998). These antibodies react with 
both isoforms of syk and do not recognize more distantly related src family members (Cell 
Signaling Technology, Beverly, MA). Strong staining for both phospho-Y352 (Fig.1A-C) and 
phospho-YY525/6 (Fig.1D-F) was observed in individual cells of independent ducts as well 
as ductules associated with acinar clusters. No staining was observed in the absence of 
primary antibody or when purified rabbit IgG was used as a control (not shown).  
  
Fig. 1. Syk is functional in pancreatic ductal cells in situ. Immunohistochemical staining 
(brown-black) of normal pancreas with phospho-Y352 (A-C) and phospho-YY525/6 (D-F). 
Arrowheads in (C,F) denote nuclear staining. Scale bars in m.  
Nuclear staining was observed in a subset of the duct cells (arrowheads in Fig.1C,F), 
consistent with the detection of nuclear syk in pancreatic ductal cells in situ (Layton et al., 
2009) and previous reports of syk nuclear translocalization (Wang et al., 2003) and 
regulation of cell division (Zyss et al., 2005) and transcription (Wang et al., 2005). Of the 20 
samples analyzed, all showed evidence of syk activation in a subset of ductal cells and none 
showed widespread constitutive phosphorylation at either site, demonstrating the active 
regulation of syk activation and activity in ductal cells of the normal human pancreas and 
suggesting an active role for syk in regulating the phenotype of this cell type.  
We also previously established the expression of syk in well- to moderately-differentiated 
PDAC cells (CAPAN2-G1, CFPAC1-G2, BxPC3-G2, AsPC1-G2), to the exclusion of poorly-
differentiated PDAC cells (Panc1-G3, MIAPaCa2-G3+)(Layton et al., 2009). In order to 
establish the utilization of syk by these endogenously syk-positive PDAC cells, we analyzed 
the activation surrogate readout of Y352 and YY525/6 phosphorylation in BxPC3 cells. 
Serum-starved cells were stimulated with insulin and then lysates immunoblotted with the 
phospho-syk-specific pAbs used for IHC. Interestingly, both Y352 and YY525/6 are 
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constitutively phosphorylated under starvation conditions, and dephosphorylated in 
response to insulin (Fig.2). Similar results were obtained with serum stimulation (not 
shown), and with endogenously syk-positive CAPAN2 cells (not shown). These data 
demonstrate the active regulation of syk activity in response to specific signalling pathways 
in endogenously syk-positive, well-differentiated PDAC cells, consistent with the restricted 
syk activation observed in situ and suggesting that syk is an active participant in regulating 
the phenotype of these cells. 
 
Fig. 2. Syk is functional in PDAC cells in vitro. Immunoblot of phospho-Y352 and 
phospho-YY525/6 in BxPC3 cells that had been serum-starved for 24h prior to stimulation 
with 10ng/ml insulin for the indicated times. NT, no treatment. Total syk levels determined 
with the 4D10 mAb are shown as a control. 
3.2 Syk-dependent regulation of cell growth requires syk kinase activity  
Syk regulates proliferation of immune cells in response to specific receptor activation events 
(Kimura et al., 1996; Sada et al., 2001; Wieder et al., 2001), and ectopic expression of an RFP-
tagged syk caused anomalous cell division and mitotic catastrophe in breast cancer cells, 
where it was observed to interact with -tubulin of the mitotic spindle (Zyss et al., 2005). We 
observed localization of syk to the perinuclear region of dividing PDAC cells (not shown), 
therefore we assessed whether syk might be involved in regulating the proliferation of 
endogenously syk-positive PDAC cells in a manner analogous to that described in breast 
cancer (Coopman et al., 2000). Consistent with such a role, the in vitro growth of 
endogenously syk-positive CAPAN2, CFPAC1, BxPC3 and AsPC1 cells was suppressed in a 
dose-dependent manner by piceatannol, a phytochemical that inhibits the kinase activity of 
syk, suppressing downstream phosphorylation events by a largely unknown mechanism  
(Geahlen et al., 1989; Ferrigni et al., 1984; Wieder et al., 2001)(Fig.3A). Significantly, the only 
G1 cells in this group, CAPAN2, were completely eradicated by the highest dose of  
inhibitor, suggesting cytotoxicity in addition to any cytostatic effect of this compound in 
these highly differentiated cells. 
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Fig. 3. Kinase activity is required for syk-dependent regulation of cell growth. (A) Cell 
growth of syk-positive versus syk-negative PDAC cell lines after 7 days of piceatannol 
treatment, plotted as percent of untreated control. (B) Proliferation of stable BxPC3/mock 
and BxPC3/sykKD cells after 5 days. (B,inset) Immunoblot of total syk (syk) and the myc-tag 
(myc) of sykKD. Erk2, loading control. (C) Proliferation of MP2/mock and MP2/sykwt cells 
after 5 days. (D) MP2/sykwt and Panc1/syk cell growth assay after 7 days of piceatannol 
treatment, as in (A). (E) Phase contrast images demonstrating the effect of stable syk 
expression on MIAPaCa2 cell morphology. Both populations were maintained under 
identical culture conditions including maintenance doses of the selectable marker 
hygromycin. (F) Effect of syk on anchorage-independent growth of MIAPaCa2 cells. A 
representative example of replicate plates is shown with quantitation points superimposed. 
The specificity of this effect to the inhibition of syk is demonstrated by the following facts. 
First, trans-stilbene, which is the base molecule from which piceatannol is derived, had no 
effect on the proliferation of any of these cells (not shown). Second, syk-negative 
MIAPaCa2 and Panc1 cells demonstrated no growth response to piceatannol in this assay 
(Fig. 3A). Third, although piceatannol has been reported to inhibit FAK, src, PI3K and 
IB/NF-B kinases (Ashikawa et al., 2002; Choi et al., 2010; Law et al., 1999), inhibition of 
these kinases has been shown to retard the proliferation of both syk-positive and syk-
negative lines used in this study (Hering et al., 2007; Hochwald, et al., 2009; Ito et al., 2003; 
Perugini et al., 2000). Together, these points demonstrate that the antiproliferative effect of 
piceatannol reported here is likely restricted to the inhibition of syk itself. It should be noted 
that the concentrations of piceatannol used in this study are based on prior established 
parameters designed to minimize non-specific effects (Ashikawa et al., 2002; Choi et al., 
2010; Geahlen et al., 1989; Law et al., 1999; Seow et al., 2002; Wieder et al., 2001). 
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To extend these pharmacological inhibitor studies, we stably transfected endogenously syk-
positive BxPC3 cells with a kinase-dead syk construct harbouring a point mutation (K402R) 
in the ATP binding site of the kinase domain (BxPC3/KD cells). This construct has been 
shown to act as a dominant-negative in endogenously syk-positive cells through an 
incompletely understood mechanism (Coopman et al., 2000). BxPC3/KD cells demonstrated 
a consistently reduced growth rate versus mock-transfectants (Fig.3B). Stable expression of 
wildtype syk did not affect the proliferation rate of these cells (not shown). It should be 
noted that these engineered cells are non-clonal populations, being the result of a bicistronic 
system that links transgene expression to drug resistance through an IRES sequence. 
Moreover, repeated generation of stable populations using this system resulted in stable 
“lines” that behaved similarly, demonstrating that these data are not artifactual in nature. 
Since stable reexpression of syk in G3 Panc1 cells reduced their growth rate in vitro (Layton 
et al., 2009), we questioned whether stable reexpression of syk in MIAPaCa2 (MP2/sykwt) 
cells would have a similar effect on these G3+ PDAC cells. Unlike Panc1 cells, no growth 
rate difference was observed between MP2/mock and MP2/sykwt cells in culture (Fig.3C). 
Moreover, piceatannol did not suppress the growth of MIAPaCa2 or Panc1 cells stably 
reexpressing syk (Fig.3D), suggesting that PDAC cells that have progressed to syk-negative 
status are able to bypass the growth requirement for endogenous syk when it is ectopically 
reintroduced. It should be noted, however, that piceatannol was functional in this assay, 
since it caused a slight dose-dependent increase in the growth rate of Panc1/syk cells 
(Fig.3D) that is commensurate with overcoming the minor growth rate reduction that 
resulted from the original stable reexpression of syk in these cells (Layton et al., 2009). In 
contrast, however, we did observe an effect of stable syk reexpression on overall MIAPaCa2 
morphology similar to that observed in Panc1/syk cells (Layton et al., 2009). As such, 
MP2/sykwt cells demonstrate increased cell-cell interactions, resulting in more of a 
traditional monolayer characteristic of epithelial cells in culture, and a reduced propensity 
for cells to remain separate in between cell clusters (Fig.3E). This suggests the 
reestablishment of a more differentiated phenotype by syk in these cells. Accordingly, 
MP2/sykwt cells demonstrate a dramatically reduced ability to grow in an anchorage-
independent growth assay (Fig.3F), exhibiting a plating efficiency of 1.7%, versus 9.0% for 
MP2/mock cells, less dramatic but similar to the effect observed previously in Panc1/syk 
cells (Layton et al., 2009). 
3.3 Stable expression, but not kinase activity, is required for syk-dependent invasion 
suppression  
We previously observed a negative regulation of Panc1 invasion by stable reexpression of 
syk (Layton et al., 2009). Therefore, we assessed the in vitro invasion capabilities of 
MP2/mock and MP2/sykwt cells. Stable MP2/sykwt cells exhibit 90% less invasion towards 
serum-containing media compared to MP2/mock, and essentially no invasion in the 
absence of serum attractant (Fig.4A). To determine whether the kinase activity of syk is 
required for this effect, we stably expressed the K402R kinase-dead (KD) mutant syk in 
MIAPaCa2 cells (MP2/sykKD); both wildtype and KD proteins were expressed at equal 
levels (Fig.4A, inset). Importantly, stable MP2/sykKD cells exhibit nearly identical invasion 
suppression to MP2/sykwt cells (Fig.4A), demonstrating that kinase activity is not required 
for syk’s invasion-suppressor function in these cells. Consistent with this finding, 48h 
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pretreatment with piceatannol did not affect the invasion of either endogenously syk-
positive BxPC3 cells or stable MP2/sykwt cells (Fig.4B). Additionally, transient transfection 
with sykwt or sykKD did not retard MIAPaCa2 invasion (Fig.4C), suggesting that long-term 
expression is required for syk to influence invasion, likely through gene expression changes 
as described previously in Panc1 cells (Layton et al., 2009).  
 
Fig. 4. Stable expression, but not kinase activity, is required for invasion suppression by 
syk. (A) The indicated stable MIAPaCa2 populations were provided serum-containing (FBS) 
or serum-free (SF) medium in the lower compartment of invasion chambers and allowed to 
invade for 24h before removal of uninvaded cells and enumeration of invaded cells. 
(A,inset) Immunoblot of ectopic syk expression with the 4D10 mAb (syk). Erk2, loading 
control. (B) Cells were pretreated for 48h with 25M piceatannol (PC) or DMSO vehicle (NT) 
prior to seeding into invasion chambers with serum-containing media in the lower 
compartment. (C) MIAPaCa2 cells were transiently cotransfected with lacZ reporter and 
empty vector (mock), or wildtype (WT) or kinase-dead (KD) syk and 48h later seeded into 
invasion chambers. After 24 hours cells were stained with x-gal and invaded transfected 
cells (blue) were enumerated and plotted as percent of mock.  
3.4 MIAPaCa2 invasion is regulated by urokinase–type plasminogen activators  
We previously demonstrated that Panc1 invasion is dependent upon the matrix 
metalloproteinase (MMP)-2 axis, and that syk specifically attenuates the expression of 
MMP2 and its inhibitor, TIMP2, in these cells (Layton et al., 2009). In contrast to Panc1 cells, 
the MMP inhibitor TAPI1 did not suppress MIAPaCa2/mock invasion (Fig.5A), and RT-
PCR (Fig.5B) and zymography (not shown) showed that MIAPaCa2 cells do not produce 
MMP2 in culture. MMP2 and MMP9 products were detected in parallel reactions run at the 
same time on unrelated samples (not shown), demonstrating that lack of signal in these 
samples is not the result of failed amplification reactions. These results demonstrate that 
MIAPaCa2 invasion is MMP-independent in vitro.  
Another key regulator of epithelial cell invasion is the urokinase-type plasminogen activator 
(uPA)/uPA receptor (uPAR) axis (Leissner et al., 2006; McMahon and Kwaan, 2009), whose 
components are expressed by MIAPaCa2 cells in culture (Fig.5B). Consistent with the 
potential involvement of this system, MP2/mock invasion was completely suppressed by 
the serine protease inhibitor aprotinin (Fig.5C). This effect was not due to toxicity, as 
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aprotinin-treated cells remained 100% viable after 24h (Fig.5C, inset), which is the duration 
of the invasion assay. Specifically demonstrating the involvement of the uPA/uPAR axis, 
MP2/mock invasion was almost completely inhibited by a function-blocking anti-uPA 
antibody (Fig.5C). An isotype-matched (IgG1) control antibody (MOPC-21) had no effect 
(not shown). Importantly, densitometry demonstrated >75% reduction in uPA mRNA levels 
by both sykwt and sykKD in MIAPaCa2 cells (Fig.5B), suggesting a potential mechanism for 
syk’s effect on MIAPaCa2 invasion. Interestingly, expression of the uPA inhibitor, PAI-1, 
was also suppressed >30% by both wildtype and kinase-dead syk (Fig.5B). However, the 
uPA receptor, uPAR, was actually increased ~50% by sykwt, but suppressed by >60% by 
sykKD, suggesting that kinase activity may be required for appropriate regulation of uPAR, 
but not uPA or PAI-1.  
 
Fig. 5. MIAPaCa2 invasion is mediated by the uPA/uPAR axis. (A) MP2/mock invasion 
towards serum-containing (FBS) or serum-free (SF) medium +/- the MMP inhibitor TAPI1. 
(B) Semi-quantitative RT-PCR from the indicated stable MIAPaCa2 transfectants for the 
indicated products. GAPDH, control. (C) MP2/mock invasion +/- the serine protease 
inhibitor aprotinin or function-blocking anti-uPA antibody. (C,inset) Viability of aprotinin-
treated cells after 24h.  
Previous studies have demonstrated the regulation of the MMP2 axis by the v3 integrin 
(Deryugina et al., 2001; Nisato et al., 2005), and an association of the uPA/uPAR axis with 
the v5 integrin (Yebra et al., 1995; 1996). Moreover, MMP2 activation has been linked to 
v3 in PDAC (Hosotani et al., 2002), and v3 engagement suppresses the expression of 
uPA/uPAR components (Hapke et al., 2001). Therefore, to assess whether the different 
protease dependencies observed in this and our former study (Layton et al., 2009) are 
related to differential integrin expression, FACS analysis was performed on live cells from 
standard culture. Consistent with MMP2-dependence, Panc1 cells proved to be strongly 
v3-positive (Fig.6A). In contrast, MIAPaCa2 cells are v3-negative (Fig.6B), 
commensurate with their MMP2-independent/uPA-dependent phenotype. These results on 
cell surface integrin expression were corroborated at the total expression level by 
immunoblotting of whole cell lysates (not shown). Further demonstrating the integrin-
dependent phenotypes of these cells, MIAPaCa2 invasion could be fully suppressed by a 
v5 integrin-specific function-blocking mAb, while Panc1 invasion also involves v3 and 
could only be fully blocked by combination of v5- and v3-specific function blocking 
mAbs (Fig.6C). 
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Fig. 6. The invasion mechanism of MIAPaCa2 and Panc1 cells is related to their integrin 
expression profiles. (A,B) FACS analysis of integrin v3 and v5 surface expression in 
Panc1 (A) and MIAPaCa2 cells (B). (C) Invasion of MIAPaCa2 (left) and Panc1 (right) cells in 
the presence or absence of 50g/ml of function-blocking antibodies directed against the 
indicated integrins.  
To further test the role of syk in regulating PDAC invasion, we examined the BxPC3/KD 
cells, which stably express the dominant-negative kinase-dead syk in addition to their 
endogenous wildtype syk. While BxPC3/mock cells show marginal invasion towards 
serum-containing media and essentially no invasion in the absence of serum attractant, 
stable BxPC3/KD cells demonstrate a >75% increase in invasion towards serum-containing 
media and significant de novo invasion in the absence of serum attractant (Fig.7A). FACS 
demonstrated that BxPC3 cells are also v3-negative (not shown) and, consistent with this 
finding, the MMP inhibitor TAPI1 had no effect on serum-free BxPC3/KD invasion (Fig.7B). 
However, both aprotinin and anti-uPA mAb treatment reduced serum-free BxPC3/KD 
invasion significantly (Fig.7B), demonstrating a role for the uPA/uPAR axis in the syk-
regulated invasion of these endogenously syk-positive PDAC cells. An isotype-matched 
(IgG1) control antibody (MOPC-21) had no effect (not shown). It should be stressed that 
BxPC3/mock cells do not invade under these conditions, thereby allowing us to assess the 
role of uPA in a phenotype that was dependent upon syk inhibition and allowing us to 
exclude confounding issues derived from the endogenous phenotype.  
4. Discussion  
Previously we identified syk as being expressed not only in normal pancreatic ductal 
epithelium, but also in well- to moderately-differentiated PDAC in situ (Layton et al., 2009). 
The expression of syk in normal ductal epithelium of the breast has also been reported, as 
has a role for syk as a tumor suppressor in that tissue (Coopman et al., 2000). As such, loss of 
syk expression in primary breast tumors is associated with a poor prognosis (Toyama et al., 
2003). We found that syk similarly correlates with patient survival in PDAC patients 
(Layton et al., 2009). However, we observe consistent loss of syk expression in poorly-
differentiated PDAC, and have not observed loss of syk in well-differentiated PDAC 
samples. This differs from breast cancer, where syk is absent from a subset of well- 
differentiated lesions and expressed normally in many poorly-differentiated samples 
(Toyama et al., 2003), suggesting potentially dramatic differences in the regulation or 
function of syk in the ductal epithelium of these two glandular tissues. Indeed, we present 
evidence that syk functions to facilitate growth of PDAC cells that express it. This is perhaps 
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Fig. 7. BxPC3 invasion is regulated by syk and mediated by the uPA/uPAR axis. 
(A) Invasion of stable BxPC3/mock (Bx/mock) and BxPC3/KD (Bx/KD) cells towards 
serum-containing (FBS) or serum-free (SF) medium. (B) Serum-free BxPC3/KD invasion +/- 
TAPI1 (left), or aprotinin or function-blocking anti-uPA antibody (right). BxPC3/mock cells 
were not assessed as they exhibit no invasion in the absence of serum in the lower chamber. 
not entirely unexpected since syk promotes immune cell proliferation in response to 
antigenic stimulation (Kimura et al., 1996; Sada et al., 2001), and vascular defects observed in 
syk-deficient mice are attributable to a reduction in endothelial cell number (Yanagi et al., 
2001). Indeed, syk was subsequently shown to be required for endothelial cell proliferation 
in vitro (Yanagi et al., 2001).  
Mechanistically, syk has been shown to regulate mitosis through direct interactions with -
tubulin and catalytic activity within the centrosome (Zyss et al., 2005). Morphological 
examination of piceatannol-treated PDAC cells stained with DAPI revealed that 
aberrant/dysfunctional mitosis may be responsible for the reduced cell numbers observed 
in this assay (not shown). This finding is consistent with prior ectopic expression studies 
that demonstrated localization of a carboxy-terminally RFP-tagged syk to centrosomes (Zyss 
et al., 2005); this chimera caused aberrant mitosis that likely resulted from steric interference 
of the RFP molecule on the directly adjacent kinase domain, further supporting our 
contention that syk kinase activity is required for syk-dependent regulation of cell division, 
and hence growth. 
Similarly, since pharmacological inhibition of syk does not affect BxPC3 invasion, but stable 
expression of sykKD does, this suggests that this effect of sykKD is not due to direct 
suppression of endogenous syk signaling in these cells. As such, this construct may function 
by sequestering binding partners that would normally be phosphorylated by catalytically 
active syk, or a similar mechanism, since this construct can still be phosphorylated by 
upstream mediators such as src. Indeed, phosphorylation of Y352 couples syk to binding 
partners such as phospholipaseC and vav through the SH2 domains of these proteins (Sada 
et al., 2001). Mutation of Y352 impairs signaling in immune cells (Sada et al., 2001), 
demonstrating that Y352 is an important regulator of syk function in these cells. The 
presence of phosphorylated Y352 in pancreatic cells in situ and in vitro suggests that these or 
similar pathways are functional in syk-mediated processes in this cell type as well. 
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Proteolytic degradation of the extracellular matrix during tumor progression often involves 
uPA, its inhibitor, PAI-1, and its receptor, uPAR (Binder and Mihalay, 2008; McMahon and 
Kwaan, 2009). This system regulates the activation of the serine protease plasmin, and in the 
pancreas uPAR has been shown to regulate PDAC phenotype through interaction with 
integrin v5 and PKC signalling (Yebra et al., 1995; 1996). More importantly, studies have 
shown a correlation between uPA and PAI-1 expression and tumor aggressiveness (Hansen 
et al., 2003), and PAI-1 has been shown to be necessary for tumor invasion (Binder and 
Mihaly, 2008). We recently reported that stable reexpression of syk dramatically reduced the 
invasion of endogenously syk-negative Panc1 cells at least partly by attenuating the MMP2 
axis (Layton et al., 2009). Herein, we demonstrate that MIAPaCa2 and BxPC3 invasion is 
MMP-independent and mediated by the urokinase/plasminogen system, and that syk 
attenuates the expression of both uPA and PAI-1. This difference in protease utilization may 
be due to the differential expression and/or involvement of specific integrins since Panc1 
cells are v3-positive while MIAPaCa2 and BxPC3 cells are v3-negative. Integrin v3 
suppresses uPA/uPAR expression in ovarian cancer cells (Hapke et al., 2001) and, as noted 
previously, the MMP2 axis has been associated with expression of the v3 integrin and 
v3 is required for MMP2 activation in some cell types (Deryugina et al., 2001); Nisato et 
al., 2005), including PDAC (Hosotani et al., 2002). Reciprocally, the uPA/uPAR axis is linked 
to v5 (Yebra et al., 1995; 1996) and other integrins including 31 (Zhu et al., 2009), which 
is also expressed by both MIAPaCa2 and BxPC3 cells (S. Silletti, unpublished data). 
Importantly, the differential integrin utilization by these cells extended to the regulation of 
invasion as well. Therefore, this differential use of protease pathways in an integrin-specific 
manner by PDAC cells may be useful from a diagnostic and/or prognostic standpoint if 
further studies bear out this relationship in this tumor type.  
In summary, we have further characterized the activity of syk in the growth and invasion 
regulation of pancreatic ductal epithelial cells. The expression of syk in these cells is 
associated with phosphorylation of tyrosines indicative of syk activation and activity, both 
in vitro and in situ, and syk activity is involved in regulating the proliferation/survival of 
syk-positive PDAC cells in vitro. This effect may be related to syk’s role in transducing 
signals from growth factor receptors, or from syk’s regulation of the mitotic spindle during 
mitosis. Irrespective, there has been a recent surge of interest in inhibitor-based strategies to 
target syk for conditions such as asthma, rheumatoid arthritis, and other immune disorders 
(Scott, 2011; Ulanova et al., 2005; Wong et al., 2004). Therefore, we propose that, aside from 
being a potential regulator of PDAC biology and biomarker of more differentiated  
PDAC tumors in situ, syk may be a viable target for therapeutic intervention in the clinic, 
since all grades of PDAC are uniformly fatal (NCI PDQ Database 
[http://www.cnacer.gov/cancertopics/pdq]; NCI-PANC-PRG) and syk expression is 
maintained in G1 and G2 PDAC in situ (Layton et al., 2009). 
5. Conclusion  
In this report we demonstrate that upstream activated and catalytically active syk kinase 
states can be detected in pancreatic ductal epithelial cells, both in vitro and in situ. The 
activity of syk is further demonstrated with regard to the regulation of cellular growth and 
invasion. Importantly, we have found that syk-dependent regulation of invasion is via 
modulation of the urokinase/plasminogen system in v3-negative PDAC cells. This is in 
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contrast to the MMP-dependent invasion-suppressor effect of syk in v3-positive PDAC 
cells, which are the exception, rather than the norm in this tumor type. These data provide 
further evidence of a central role for syk in regulating pancreatic ductal epithelial cell 
phenotype, and support the potential utility of targeting syk as a potential therapeutic 
modality in well- to moderately-differentiated PDAC patients, which are the majority of 
clinical cases. The significance of this is highlighted by the fact that PDAC is characterized 
by extensive dissemination at the time of diagnosis, irrespective of grade of disease. 
6. Acknowledgement  
S.Silletti is an American Cancer Society Research Scholar supported by ACS RSG-05-116-01-
CSM and NIH grants CA130104 and CA109956. Funding agencies had no role in study 
design/performance or manuscript preparation. Moores UCSD Cancer Center is an NCI-
sponsored Comprehensive Cancer Center supported by NCI Specialized Support Grant P30 
CA23100. 
7. References 
Ashikawa K, Majumdar S, Banerjee S, Bharti AC, Shishodia S, Aggarwal BB. (2002). 
Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated 
gene expression through suppression of IkappaBalpha kinase and p65 
phosphorylation. J Immunol, 169, 6490-6497. 
Binder BR, Mihaly J. (2008). The plasminogen activator inhibitor "paradox" in cancer. 
Immunol Lett, 118, 116-124. 
Chen MM, Lee C-Y, Leland HA, Lin GY, Montgomery AM, Silletti S. (2010). Inside-out 
regulation of L1 conformation, integrin binding, proteolysis, and concomitant cell 
migration. Mol Biol Cell, 21, 1671-1685. 
Choi KH, Kim JE, Song NR, Son JE, Hwang MK, Byun S, Kim JH, Lee KW, Lee HJ. (2010). 
Phosphoinositide 3-kinase is a novel target of piceatannol for inhibiting PDGF-BB-
induced proliferation and migration in human aortic smooth muscle cells. 
Cardiovasc Res, 85, 836-844. 
Coopman PJ, Do MT, Barth M, Bowden ET, Hayes AJ, Basyuk E, Blancato JK, Vezza PR, 
McLeskey SW, Mangeat PH, Mueller SC. (2000). The syk tyrosine kinase suppresses 
malignant growth of human breast cancer cells. Nature, 406, 742-747. 
Deryugina EI, Ratnikov B, Monosov E, Postnova TI, DiScipio R, Smith JW, Strongin AY. 
(2001). MT1-MMP initiates activation of pro-MMP-2 and integrin v3 promotes 
maturation of MMP-2 in breast carcinoma cells. Exp Cell Res, 263, 209-223. 
Ferrigni NR, McLaughlin JL, Powell RG, Smith CR, Jr. (1984). Use of potato disc and brine 
shrimp bioassays to detect activity and isolate piceatannol as the antileukemic 
principle from the seeds of Euphorbia lagascae. J Nat Prod, 47, 347-352. 
Geahlen RL, McLaughlin JL. (1989). Piceatannol (3,4,3’,5’-tetrahydroxy-trans-stilbene) is a 
naturally occurring protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun, 
165, 241-245. 
Hansen S, Overgaard J, Rose C, Knoop A, Laenkholm AV, Andersen J, Sørensen FB, 
Andreasen PA. (2003). Independent prognostic value of angiogenesis and the level 
of plasminogen activator inhibitor type 1 in breast cancer patients. Br J Cancer, 88, 
102-108. 
www.intechopen.com
Kinase Activity is Required for Growth Regulation but not 
Invasion Suppression by Syk Kinase in Pancreatic Adenocarcinoma Cells 
 
117 
Hapke S, Kessler H, Arroyo de Prada N, Benge A, Schmitt M, Lengyel E, Reuning U. (2001). 
Integrin v3/vitronectin interaction affects expression of the urokinase system in 
human ovarian cancer cells. J Biol Chem, 276, 26340-26348.  
Hering J, Garrean S, Dekoj TR, Razzak A, Saied A, Trevino J, Babcock TA, Espat NJ. (2007). 
Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic 
cancer cells. Ann Surg Oncol, 14, 3620-3628. 
Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, Magis A, Ostrov D, 
Cance WG, Golubovskaya VM. (2009). A novel small molecule inhibitor of FAK 
decreases growth of human pancreatic cancer. Cell Cycle, 8, 2435-2443. 
Hosotani R, Kawaguchi M, Masui T, Koshiba T, Ida J, Fujimoto K, Wada M, Doi R, Imamura 
M. (2002). Expression of integrin v3 in pancreatic carcinoma: relation to MMP-2 
activation and lymph node metastasis. Pancreas, 25, e30-35. 
Ito H, Gardner-Thorpe J, Zinner MJ, Ashley SW, Whang EE. (2003). Inhibition of tyrosine 
kinase Src suppresses pancreatic cancer invasiveness. Surgery, 134, 221-226. 
Kimura T, Sakamoto H, Appella E, Siraganian RP. (1996). Conformational changes induced 
in protein tyrosine kinase p72syk by tyrosine phosphorylation or by binding of 
phosphorylated immunoreceptor tyrosine-based activation motif peptides. Mol Cell 
Biol, 16, 1471-1478. 
Law DA, Nannizzi-Alaimo L, Ministri K, Hughes PE, Forsyth J, Turner M, Shattil SJ, 
Ginsberg MH, Tybulewicz VL, Phillips DR. (1999). Genetic and pharmacological 
analyses of Syk function in IIb3 signaling in platelets. Blood, 93, 2645-2652. 
Layton T, Stalens C, Gunderson F, Goodison S, Silletti S. (2009). Syk tyrosine kinase acts as a 
pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and 
invasion. Am J Pathol, 175, 2625-2637. 
Leissner P, Verjat T, Bachelot T, Paye M, Krause A, Puisieux A, Mougin B. (2006). Prognostic 
significance of urokinase plasminogen activator and plasminogen activator 
inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive 
breast cancer. BMC Cancer, 6, 216. 
McMahon B, Kwaan HC. (2009). The plasminogen activator system and cancer. Pathophysiol 
Haemost Thromb, 236, 184-194. 
National Cancer Institute PDQ Database [http://www.cancer.gov/cancertopics/pdq] 
NCI-Pancreatic Cancer Progress Review Group: National Cancer Institute Strategic plan for 
addressing the recommendations of the Pancreatic Cancer Progress Review Group. 
(2002). PANC-PRG Implementation Plan. Bethesda, MD USA. National Cancer 
Institute. 
Nisato RE, Hosseini G, Sirrenberg C, Butler GS, Crabbe T, Docherty AJ, Wiesner M, Murphy 
G, Overall CM, Goodman SL, Pepper MS. (2005). Dissecting the role of matrix 
metalloproteinases (MMP) and integrin v3 in angiogenesis in vitro: absence of 
hemopexin C domain bioactivity, but membrane-Type 1-MMP and v3 are 
critical. Cancer Res, 65, 9377-9387. 
Perugini RA, McDade TP, Vittimberga FJ Jr, Callery MP. (2000). Pancreatic cancer cell 
proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res. 90, 39-44. 
Sada K, Takano T, Yanagi S, Yamamura H. 2001. Structure and function of syk protein-
tyrosine kinase. J Biochem, 130, 177-186. 
Scott, DL. (2011). Role of spleen tyrosine kinase inhibitors in the management of rheumatoid 
arthritis. Drugs, 71, 1121-1132. 
www.intechopen.com
 Pancreatic Cancer – Molecular Mechanism and Targets 
 
118 
Seow CJ, Chue SC, Wong WS. (2002). Piceatannol, a Syk-selective tyrosine kinase inhibitor, 
attenuated antigen challenge of guinea pig airways in vitro. Eur J Pharmacol, 443, 
189-96. 
Toyama T, Iwase H, Yamashita H, Hara Y, Omoto Y, Sugiura H, Zhang Z, Fujii Y. (2003). 
Reduced expression of the Syk gene is correlated with poor prognosis in human 
breast cancer. Cancer Lett, 189, 97-102. 
Ulanova M, Duta F, Puttagunta L, Schreiber AD, Befus AD. (2005). Spleen tyrosine kinase 
(Syk) as a novel target for allergic asthma and rhinitis. Expert Opin Ther Targets, 9, 
901-921. 
Wang L, Duke L, Zhang PS, Arlinghaus RB, Symmans WF, Sahin A, Mendez R, Dai JL. 
(2003). Alternative splicing disrupts a nuclear localization signal in spleen tyrosine 
kinase that is required for invasion suppression in breast cancer. Cancer Res, 63, 
4724-4730. 
Wang L, Devarajan E, He J, Reddy SP, Dai JL. (2005). Transcription repressor activity of 
spleen tyrosine kinase mediates breast cancer suppression. Cancer Res, 65, 10289-
10297. 
Wieder T, Prokop A, Bagci B, Essmann F, Bernicke D, Schulze-Osthoff K, Dörken B, Schmalz 
HG, Daniel PT, Henze G. (2001). Piceatannol, a hydroxylated analog of the 
chemopreventive agent resveratrol, is a potent inducer of apoptosis in the 
lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia, 15, 
1735-1742. 
Wong BR, Grossbard EB, Payan DG, Masuda ES. (2004). Targeting Syk as a treatment for 
allergic and autoimmune disorders. Expert Opin Investig Drugs, 13, 743-762. 
Yanagi S, Inatome R, Takano T, Yamamura H. (2001). Syk expression and novel function in a 
wide variety of tissues. Biochem Biophys Res Commun, 288:495-498. 
Yebra M, Parry GC, Strömblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA. 
(1996). Requirement of receptor-bound urokinase-type plasminogen activator for 
integrin v5-directed cell migration. J Biol Chem., 271, 29393-29399. 
Yebra M, Filardo EJ, Bayna EM, Kawahara E, Becker JC, Cheresh DA. (1995). Induction of 
carcinoma cell migration on vitronectin by NF-kappa B-dependent gene 
expression. Mol Biol Cell, 6, 841-50. 
Zhang J, Kimura T, Siriganian RP. (1998). Mutations in the activation loop tyrosines of 
protein tyrosine kinase syk abrogate intracellular signaling but not kinase activity. J 
Immunol, 161, 4366-4374. 
Zhu S, Gladson CL, White KE, Ding Q, Stewart J Jr, Jin TH, Chapman HA Jr, Olman MA. 
(2009). Urokinase receptor mediates lung fibroblast attachment and migration 
toward provisional matrix proteins through interaction with multiple integrins. A J 
Physiol Lung Cell Mol Physiol, 297, L97-L108. 
Zyss D, Montcourrier P, Vidal B, Anguille C, Mérezègue F, Sahuquet A, Mangeat PH, 
Coopman PJ. (2005). The syk tyrosine kinase localizes to the centrosomes and 
negatively affects mitotic progression. Cancer Res, 65, 10872-10880. 
www.intechopen.com
Pancreatic Cancer - Molecular Mechanism and Targets
Edited by Prof. Sanjay Srivastava
ISBN 978-953-51-0410-0
Hard cover, 432 pages
Publisher InTech
Published online 23, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book provides the reader with an overall understanding of the biology of pancreatic cancer, hereditary,
complex signaling pathways and alternative therapies. The book explains nutrigenomics and epigenetics
mechanisms such as DNA methylation, which may explain the etiology or progression of pancreatic cancer.
Book also summarizes the molecular control of oncogenic pathways such as K-Ras and KLF4. Since
pancreatic cancer metastasizes to vital organs resulting in poor prognosis, special emphasis is given to the
mechanism of tumor cell invasion and metastasis. Role of nitric oxide and Syk kinase in tumor metastasis is
discussed in detail. Prevention strategies for pancreatic cancer are also described. The molecular mechanisms
of the anti-cancer effects of curcumin, benzyl isothiocyante and vitamin D are discussed in detail. Furthermore,
this book covers the basic mechanisms of resistance of pancreatic cancer to chemotherapy drugs such as
gemcitabine and 5-flourouracil.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Tracy Layton, Felizza Gunderson, Chia-Yao Lee, Cristel Stalens and Steve Silletti (2012). Kinase Activity is
Required for Growth Regulation but not Invasion Suppression by Syk Kinase in Pancreatic Adenocarcinoma
Cells, Pancreatic Cancer - Molecular Mechanism and Targets, Prof. Sanjay Srivastava (Ed.), ISBN: 978-953-
51-0410-0, InTech, Available from: http://www.intechopen.com/books/pancreatic-cancer-molecular-
mechanism-and-targets/kinase-activity-is-required-for-growth-regulation-but-not-invasion-suppression-by-syk-
kinase-in-panc
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
